AnGes Inc (AnGes) develops gene technologies for the treatment of pain and lung-related diseases. The company focuses on genetic medicine and specializes in genetic and nucleic acid medicine. It develops products for the treatment of chronic arterial occlusive disease, chronic discogenic lumbar back pain, and DNA vaccines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AnGes is actively engaged in the research and development of genetic medicine, focusing on the development and practical application of pharmaceuticals. The company is working on genome editing, considered the ultimate form of gene therapy, for diseases that have been challenging to treat. AnGes is also involved in the development of HGF gene therapy products, NF-?B decoy oligonucleotide DNA, DNA vaccines for hypertension and COVID-19, and Tie2 receptor agonists. The company has established a subsidiary, Emendo, to advance genome editing technology and has entered into various collaborations to enhance its R&D efforts. AnGes Clinical Research Laboratory (ACRL) is responsible for performing testing for rare genetic diseases. It provides testing services for optional screening and expanded newborn screening for rare genetic diseases. ACRL is also involved in biomarker testing to monitor the effectiveness of treatment. It also has the Tonomachi R&D Center (CMC/Drug Discovery Research), which is involved in drug discovery research and development activities. The company has applied for patents related to the OMNI Platform and OMNI nucleases developed by its subsidiary, Emendo. Some of its pipeline drugs include the HGF gene therapy product in Phase III for Chronic arterial occlusive disease with lower limb ulcer in Israel and Turkey; NF-?B Decoy Oligonucleotide in Phase II for chronic discogenic lumbar back pain in Japan; DNA Vaccine for Hypertension in Phase II in Australia; and Tie2 agonists for COVID-19 / ARDS in Phase II in the US. In FY2025, the company spent JPY3,553 million on its R&D activities, which declined 6% YoY.